氟哌噻吨美利曲辛治疗伴焦虑抑郁的慢性阻塞性肺疾病的meta分析

A meta-analysis of flupentixol and melitracen tablets in the treatment of chronic obstructive pulmonary disease with anxiety and/or depression

目的评价氟哌噻吨美利曲辛治疗伴有焦虑抑郁的慢性阻塞性肺疾病的临床疗效。方法检索PubMed、Sciencedirect数据库、中国知网、万方数据库、维普中文期刊全文数据库中关于氟哌噻吨美利曲辛治疗伴焦虑抑郁的慢性阻塞性肺疾病的相关随机对照试验,检索时限为2010年1月-2019年12月。2名研究员独立筛选文献、提取数据,采用RevMan 5.3软件对结果进行meta分析。结果共纳入9篇文献,1123例患者。试验组567例,接受氟哌噻吨美利曲辛加对症支持治疗;对照组556例,接受单纯对症支持治疗。治疗后试验组汉密尔顿焦虑量表评分[均数差(mean difference,MD)=-5.10分,95%置信区间(confidence interval,CI)(-7.67,-2.54)分,P<0.0001]、汉密尔顿抑郁量表评分[MD=-3.94分,95%CI(-6.64,-1.23)分,P=0.004]均低于对照组,且在第1秒用力呼气容积占预计值百分比[MD=4.89%,95%CI(0.59%,9.19%),P=0.03]、慢性阻塞性肺疾病评估测试评分[MD=-3.21分,95%CI(-3.76,-2.66)分,P<0.00001]方面优于对照组。结论氟哌噻吨美利曲辛加对症支持治疗对伴焦虑抑郁的慢性阻塞性肺疾病有较好的效果,在改善临床症状方面优于单纯对症支持治疗。

Objective To evaluate the clinical efficacy of flupentixol and melitracen tablets on the treatment of chronic obstructive pulmonary disease(COPD)with anxiety and/or depression.Methods Randomized controlled trials of flupentixol and melitracen tablets in the treatment of COPD with anxiety and/or depression were retrieved from PubMed,Sciencedirect Database,China National Knowledge Infrastructure,Wanfang Database,and CQVIP Journal Database,with retrieval time from January 2010 to December 2019.Two researchers screened literature and extracted data independently,and meta-analyzed the results using RevMan 5.3 software.Results A total of 9 articles with 1123 patients were included.There were 567 patients in the trial group receiving flupentixol and melitracen tablets plus symptomatic support therapy and 556 patients in the control group receiving simple symptomatic treatment.After treatment,the Hamilton Anxiety Scale score[mean difference(MD)=-5.10,95%confidence interval(CI)(-7.67,-2.54),P<0.0001]and Hamilton Depression Scale score[MD=-3.94,95%CI(-6.64,-1.23),P=0.004]in the trial group were lower than those in the control group,while the forced expiratory volume in one second as percentage of predicted volume[MD=4.89%,95%CI(0.59%,9.19%),P=0.03]and COPD Assessment Test score[MD=-3.21,95%CI(-3.76,-2.66),P<0.00001]in the trial group were better than those in the control group.Conclusion Flupentixol and melitracen tablets plus symptomatic support therapy has a better effect than simple symptomatic support treatment on COPD with anxiety and/or depression.